Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 02:33PM ET
1.22
Dollar change
-0.12
Percentage change
-9.19
%
Index- P/E- EPS (ttm)-1.12 Insider Own6.41% Shs Outstand29.83M Perf Week-2.65%
Market Cap36.30M Forward P/E- EPS next Y-0.82 Insider Trans0.00% Shs Float27.92M Perf Month24.17%
Income-27.62M PEG- EPS next Q-0.21 Inst Own22.86% Short Float3.74% Perf Quarter131.79%
Sales8.55M P/S4.25 EPS this Y18.89% Inst Trans-3.59% Short Ratio4.81 Perf Half Y-52.28%
Book/sh0.51 P/B2.41 EPS next Y15.75% ROA-52.47% Short Interest1.04M Perf Year-71.03%
Cash/sh0.99 P/C1.22 EPS next 5Y15.00% ROE-138.93% 52W Range0.47 - 7.46 Perf YTD106.25%
Dividend Est.- P/FCF- EPS past 5Y7.86% ROI-157.99% 52W High-83.69% Beta0.87
Dividend TTM- Quick Ratio1.20 Sales past 5Y9.88% Gross Margin81.72% 52W Low158.75% ATR (14)0.11
Dividend Ex-Date- Current Ratio1.28 EPS Y/Y TTM-9.37% Oper. Margin-458.21% RSI (14)54.87 Volatility7.86% 9.53%
Employees79 Debt/Eq1.40 Sales Y/Y TTM-55.67% Profit Margin-323.16% Recom2.33 Target Price8.50
Option/ShortYes / Yes LT Debt/Eq0.18 EPS Q/Q89.36% Payout- Rel Volume1.13 Prev Close1.34
Sales Surprise7.56% EPS Surprise69.23% Sales Q/Q-19.49% EarningsMar 27 AMC Avg Volume217.02K Price1.22
SMA205.78% SMA5025.54% SMA200-43.72% Trades Volume194,596 Change-9.19%
Date Action Analyst Rating Change Price Target Change
Oct-30-20Initiated Chardan Capital Markets Buy $7
Oct-12-20Initiated ROTH Capital Buy
Jul-31-20Initiated Oppenheimer Outperform $7
Jan-31-20Initiated B. Riley FBR Buy $5
Nov-18-19Resumed Cantor Fitzgerald Overweight
Sep-06-19Initiated Cantor Fitzgerald Overweight $5
Mar-06-18Upgrade H.C. Wainwright Neutral → Buy $3.50
Oct-20-17Reiterated Laidlaw Buy $3 → $2
Oct-20-17Downgrade Stifel Buy → Hold $3 → $0.90
Oct-20-17Downgrade H.C. Wainwright Buy → Neutral
Mar-27-24 08:53PM
05:10PM
04:19PM
04:01PM
Mar-20-24 04:30PM
07:00AM Loading…
Mar-04-24 07:00AM
Feb-07-24 06:48PM
Nov-14-23 08:05AM
Nov-13-23 04:40PM
04:05PM
Nov-09-23 04:30PM
Nov-08-23 08:40AM
07:59AM
Nov-07-23 04:01PM
Oct-19-23 10:44AM
03:07PM Loading…
Oct-02-23 03:07PM
Sep-07-23 07:00AM
Aug-31-23 04:30PM
Aug-14-23 07:55AM
Aug-10-23 07:08AM
Aug-09-23 05:50PM
04:43PM
04:05PM
Aug-03-23 04:30PM
Jul-28-23 04:19PM
Jul-20-23 08:00AM
Jun-07-23 06:00AM
May-11-23 09:55AM
May-08-23 05:25PM
04:23PM
04:05PM Loading…
04:05PM
May-01-23 07:03PM
Apr-27-23 05:11PM
Apr-25-23 06:45PM
Apr-10-23 06:00AM
Mar-24-23 06:30AM
Mar-21-23 04:30PM
Mar-11-23 07:33AM
Mar-09-23 08:30AM
Mar-08-23 05:53AM
Mar-07-23 05:35PM
04:05PM
Feb-28-23 06:07PM
Feb-17-23 06:30AM
Feb-03-23 05:17PM
Jan-11-23 07:59AM
Nov-28-22 06:46PM
Nov-02-22 06:05PM
04:05PM
Oct-26-22 08:30AM
Oct-06-22 08:30AM
Sep-26-22 08:30AM
Sep-06-22 08:00AM
Aug-08-22 06:09AM
Aug-04-22 07:35PM
04:05PM
Jul-27-22 04:15PM
Jul-24-22 08:41AM
Jul-15-22 06:15AM
Jul-05-22 08:30AM
Jun-18-22 08:05AM
May-31-22 06:21AM
May-18-22 01:53PM
May-08-22 08:19AM
May-04-22 06:25PM
04:05PM
Apr-27-22 04:15PM
Mar-24-22 09:30AM
Mar-23-22 04:15PM
01:29PM
Mar-09-22 04:30PM
Mar-07-22 05:25PM
04:05PM
Mar-01-22 08:30AM
Feb-28-22 04:30PM
09:15AM
Jan-13-22 10:00AM
Jan-06-22 04:05PM
Dec-22-21 07:30AM
05:45AM
Dec-14-21 09:00AM
Nov-29-21 09:00AM
Nov-12-21 09:00AM
Nov-10-21 09:00AM
Nov-08-21 09:00AM
Nov-07-21 07:45AM
Nov-02-21 06:15PM
04:05PM
Oct-26-21 09:00AM
Oct-25-21 03:01PM
Oct-07-21 09:00AM
Sep-23-21 09:00AM
Sep-15-21 09:00AM
Sep-07-21 09:00AM
Aug-09-21 05:29AM
Jul-29-21 07:25PM
04:05PM
Jul-22-21 08:30AM
Jul-14-21 04:30PM
Jun-25-21 09:37AM
DURECT Corp. focuses on advancing novel and potentially lifesaving investigational therapies derived from its Epigenetic Regulator Program. Its pipeline is called DUR-928, an endogenous sulfated oxysterol and an epigenetic regulator. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA.